Contemporary HIV Treatment and Prevention 2022: Optimizing HIV Outcomes in Challenging Scenarios

Download slides to review expert insights into strategies for overcoming virologic failure in heavily treatment–experienced patients and selecting optimized switch regimens for virologically suppressed patients with underlying resistance and significant potential drug–drug interactions.
Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Eric S. Daar, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 423 KB
Released: July 1, 2022

Acknowledgements

Jointly provided by the Association of Nurses in AIDS Care and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
ViiV Healthcare

Related Content

Safety and efficacy of broadly neutralizing antibody VRC01 with early ART in infants with HIV, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

ANDES: Wk 48 safety and efficacy of generic darunavir/ritonavir + lamivudine for initial HIV treatment, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Expert summaries of ART treatment initiation in treatment-naive PWH, including rapid and same-day ART starts, from Clinical Care Options (CCO)

Babafemi Taiwo, MBBS
Program Director
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Released: August 4, 2022

Week 48 results from ALLIANCE study of BIC/FTC/TAF vs DTG plus FTC/TDF for HIV/HBV coinfection, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings